Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Humana Inc (HUM) vs Koninklijke Philips NV (PHG) Price & Performance

Humana IncTrade
Koninklijke Philips NVTrade

Price performance (Past 24H)

Key statistics

Humana Inc vs Koninklijke Philips NV — how do they compare? Humana Inc trades at $405.62 (market cap $47.81B), while Koninklijke Philips NV trades at $26.55 (market cap $26.19B). The key difference: Humana Inc is the larger of the two by market cap, and Koninklijke Philips NV pays the higher dividend (3.79%). Which is the better fit depends on your goals.

HUMPHG
Market Cap
$47.81B$26.19B
Sector
HealthHealth
52-Week High
$409.42$32.91
52-Week Low
$163.67$24.54
Enterprise Value
$56.85B$32.46B
Dividend Yield
0.89%3.79%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Humana Inc

Humana (HUM) trades at $398.09, down 0.48% with a bullish technical signal from moving averages. The company shows strong revenue growth to $129.66B in 2025 but faces margin compression with net income margin declining to 0.82%. Recent earnings have consistently beaten expectations, and analyst sentiment is mixed with 34% buy ratings but a consensus price target of $354.33 below current levels.

The outlook suggests cautious optimism with Medicare Advantage expansion opportunities but significant margin pressure and regulatory risks. Key investment considerations include the company's ability to achieve its 3% Medicare Advantage margin target by 2028 while navigating increased healthcare utilization costs and competitive pressures in the insurance sector.

Koninklijke Philips NV

PHG trades at $26.80, down 0.56% with bearish technical signals. The company shows improved fundamentals with net income turning positive to $895M in 2025 after previous losses, though revenue declined slightly to $17.83B. Analyst consensus is mixed with 40.9% buy ratings but technical indicators show selling pressure. Recent developments include FDA clearances for AI-powered medical devices and strategic healthcare partnerships.

PHG presents a turnaround story with profitability recovery but faces execution risks amid competitive pressures. The stock offers value at reasonable valuations (P/E 23.67, P/S 1.29) but requires monitoring of revenue stabilization and AI product adoption. Near-term catalyst includes Q2 2026 earnings with expected EPS of $0.40.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Humana Inc

Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.

Read more on HUM

About Koninklijke Philips NV

Philips is a diversified global healthcare company operating in three segments: diagnosis and treatment, connected care, and personal health. About 50% of the company's revenue comes from the diagnosis and treatment segment, which features imaging systems, ultrasound equipment, image-guided therapy solutions and healthcare informatics. The connected care segment (27% of revenue) encompasses monitoring and analytics systems for hospitals and sleep and respiratory care devices, whereas the personal health business (remainder of revenue) includes electric toothbrushes and men's grooming and personal-care products. In 2021, Philips generated EUR 17.2 billion in sales and had 80,000 employees in over 100 countries.

Read more on PHG